Plasma biomarker progression across the Alzheimer's disease amyloid beta and tau positron emission tomography trajectories

While the studied biomarkers proved their utility to predict Aβ and tau PET at their respective thresholds, each has separate quantified responses to Aβ and tau aggregation.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2026-02-01
DOI
https://doi.org/10.1002/alz.71145
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Plasma biomarker progression across the Alzheimer's disease amyloid beta and tau positron emission tomography trajectories

Manu Vandijck, Anthony W. Bannon, Sulantha Mathotaarachchi, Azadeh Feizpour et al.
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
article

Plasma biomarker progression across the Alzheimer's disease amyloid beta and tau positron emission tomography trajectories

Manu Vandijck, Anthony W. Bannon, Sulantha Mathotaarachchi, Azadeh Feizpour, Gallen Triana‐Baltzer, Ziad S. Saad, Hartmuth C. Kolb, Henrik Zetterberg, Pierrick Bourgeat, Jurgen Fripp, Colin L. Masters, Christopher C. Rowe, Rodrigo Cánovas, Christopher J. Fowler, Stephanie Rainey‐Smith, Simon Laws, Gwendlyn Kollmorgen, Kaj Blennow, Clara Quijano‐Rubio, James D. Doecke
article en

Abstract

While the studied biomarkers proved their utility to predict Aβ and tau PET at their respective thresholds, each has separate quantified responses to Aβ and tau aggregation.

Alzheimer s & DementiaVol. 22(2)
Roche (Switzerland) (CH), Edith Cowan University (AU), Commonwealth Scientific and Industrial Research Organisation (AU), Johnson & Johnson (United States) (US), University of Wisconsin–Madison (US), Murdoch University (AU), The University of Western Australia (AU), Curtin University (AU), Florey Institute of Neuroscience and Mental Health (AU), Sahlgrenska University Hospital (SE), AbbVie (United States) (US), Roche Pharma AG (Germany) (DE), Enigma Diagnostics (United Kingdom) (GB), Australian e-Health Research Centre (AU), Australian Alzheimer’s Research Foundation (AU), National Hospital for Neurology and Neurosurgery (GB), Austin Health (AU), University College London (GB), Fujirebio (Belgium) (BE), University of Gothenburg (SE)
Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Biogen, Familjen Erling-Perssons Stiftelse, Cure Alzheimer's Fund, Stiftelsen för Gamla Tjänarinnor, EU Joint Programme – Neurodegenerative Disease Research, National Institute for Health and Care Research, University College London, European Commission, Eisai, Hjärnfonden, Vetenskapsrådet, UK Dementia Research Institute, HORIZON EUROPE Framework Programme, National Health and Medical Research Council
Openalex Percentile: Top 62%
Dementia and Cognitive Impairment Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.